In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products ...

Cencora, Inc. COR reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $4.42, which beat the Zacks Consensus Estimate of $4.08 by 8.3%. The bottom line also improved 16.3% year ...

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. Cencora (NYSE:COR) announced a notable 15% price ...

The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and ...

May 7 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today. [Operator Instructions] I ...

Has Cencora (COR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Cencora is a member of our Medical group, which includes 1002 ...